DISHMAN

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Board of Directors of the Company, at their meeting held on May 29, 2010, has decided and resolved to convene and hold the Annual General Meeting of the Members of the Company on July 30, 2010 and the Register of Members & Share Transfer Books of the Company will remain closed from July 17, 2010 to July 30, 2010 (both days inclusive) for determining the entitlement of Final Dividend as recommended as well as for holding the Annual General Meeting on July 30, 2010.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Board of Directors, at its meeting held on May 29, 2010, has approved the proposal of issue of further (second trench of) Secured Redeemable Non-Convertible Debentures up to an amount of INR 750 million.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Board of Directors at its Meeting held on May 29, 2010 has recommended payment of dividend @ 60% on the paid up equity share capital of Rs. 16,13,94,272/- (i.e. Rs. 1.20 per equity share of Rs. 2/- each) for the Financial Year 2009-10, subject to approval of members in the ensuing Annual General Meeting.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that "The Company has decided to publish audited financial results for the accounting year ended 31st March, 2010 within the stipulated period of 60 (sixty) days (i.e. on or before 30th May, 2010) from the end of the financial year 2009-2010 as stipulated in the listing agreement. Thus, the unaudited financial results for the last quarter of the accounting year ended 31st March, 2010 will not be published".

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that Dishman's Bavla Facilities are approved by Therapeutic Goods Administration (TGA), Department of Health and Ageing, Australian Government, Australia, for all Active Pharmaceutical Ingredients (API) production.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Company has, on February 18, 2010, made allotment of 75 (Seventy Five only) Secured Redeemable Non Convertible Debentures (NCDs) of face value of Rs.1.00 Crore (Rupees One Crore only) each, in forms of Separately Transferable Redeemable Principal Parts (STRPPS) of having the face value of Rs.10.00 lakhs (Rupee Ten lakhs only) each, aggregating Rs.75.00 Crores (Rupees Seventy Five Crores only).

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange regarding a strategic alliance with Codexis, Inc., California. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/dishman_updates_18022010.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that "US FDA team has successfully completed inspection of Dishman's EOU facility situated at its Naroda works, Ahmedabad and approved the said facility for API production for US market".

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange regarding the commissioning of its world-class High containment API facility for manufacture of a range of Oncology APIs and other related high potency products at its Bavla complex, near Ahmedabad. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Dishmam_update_21012010.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Board of Directors of the Company has, in its meeting held on January 12, 2010, approved the proposal of issue of Non- Convertible Debentures (NCD) up to an amount of INR 750 million, for augmenting medium to long term resources of the Company, including regular capital expenditure.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that :"(1) A new Vitamin-D Analogue facility was inaugurated and started on November 27, 2009 in the facility situated in Veenendaal, the Netherlands, which was acquired by Dishman two years back from Solvay Pharmaceuticals, Netherlands. The total investment in the project is Rs.35 Crores and with this facility, Dishman Netherlands will be the only company in the world having more than Seven Vitamin-D Analogues manufacturing capability. (2) The Pharmaceuticals & Chemicals Special Economic Zone (SEZ) of Dishman Infrastructu

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the auditors have conducted the limited review for the un-audited financial results for the quarter ended June 30,2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DISHMAN_LR_04092009.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has submitted the Exchange the copy of Newspaper cutting evidencing the publication of the Notice of Result of the Postal Ballot, duly published on August 01, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Dishman_PBRes_10082009.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange regarding Declaration of Result of Resolution passed through Postal Ballot. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DISHMAN_RPB_31072009.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange regarding the outcome of Annual General Meeting held on July 31, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DISHMAN_outcome_31072009.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the final dividend @ 60% (Rs. 1.20/- per equity share of Rs. 2/- each) as recommended by the Board and if declared by the members in the next Annual General Meeting as fixed on July 31, 2009 will be paid on and from August 04, 2009.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that Notice is hereby given pursuant to Section 192A of the Companies Act 1956, read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, consent of the Members under Section 293(1)(a) of the Companies Act, 1956 is required to be obtained by means of voting by Postal ballot. A copy of Notice of the Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corpora

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange vide its letter dated June 01, 2009, that: "The Board of Directors of the Company has taken today, the following decisions: 1) Mr. Janmejay R. Vyas, Managing Director of the Company is appointed as Chairman of the Company and his designation has been changed to Chairman & Managing Director w.e.f. 1st June, 2009. 2) Mr. Arpit J. Vyas is appointed as an Additional Director of the Company w.e.f. 1st June, 2009. He has also been appointed as Whole-time Director of the Company for a period of five years w.e.f. 1st June, 2009 su

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that Shri Rajnikant T. Vyas, Chairman of the Company(Father of Mr. Janmejay R. Vyas, Managing Director of the Company), aged about 85 years, expired in the late evening on May 27, 2009, due to ill health.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the Board meeting held on May 25, 2009, among others, the following decisions were taken by the Board of Directors of the Company : 1) Resolution in respect of the Re-appointment of Mr. Janmejay R. Vyas as Managing Director of the Company for a further period of 5 (five) years w.e.f. March 01, 2010 and payment of remuneration to him has been passed, subject to approval of the Members in ensuing Annual General Meeting to be held on July 31, 2009 and also subject to approval of Central Government, if any required. Th

Dishman Pharmaceuticals And Chemicals Limited has submitted to the Exchange information required under Clause 20 of the listing agreement i.e. Statement of Appropriations. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/dishman_app_26052009.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Company has announced the Book Closure date from July 16, 2009 to July 31, 2009 (Both days inclusive). The books are closed for determining the entitlement of final dividend, which was recommended by the Board @ 60% (i.e. Rs.1.20 per equity share of Rs.2.00 each) for the year 2008-09 and also for holding the Annual General Meeting on July 31, 2009.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Board of Directors at its meeting held on May 25, 2009 has recommended payment of dividend @60% on the paid up share capital (i.e. Rs.1.20/- per equity share of Rs.2/- each) for the Financial year 2008-09, subject to approval of members in the ensuing Annual General Meeting.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that "The Company has decided to publish audited financial results for the accounting year ended 31st March, 2009 within the stipulated period of 3 (three) months (i.e. on or before 30th June, 2009) from the end of the financial year 2008-2009 as stipulated in the listing agreement. Thus, the unaudited financial results for the last quarter of the accounting year ended 31st March, 2009 will not be published".

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that "The Board of Directors of the Company has approved a proposal to invest into a formulation facility at the Company's Bavla plant in its meeting held on 30th March, 2009. Purpose of this formulation facility is to become a full service provider as a CRAM Company. Company will invest around Rs.35.00 Crores from cash accruals to create this US FDA and MHRA approvable facility. As per management of the company, Dishman has no plans to enter generic formulation market and this facility is to cater to its customers as a fu

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that Dishman Pharma - India and Polpharma - Poland have signed a cooperation and joint API development agreement. Polpharma is in particularly a strong player in its home market and a leader in the Central and Eastern European markets and CIS countries with a turnover of ca 400 million US dollars.The detalis of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/dishman

Dishman Pharmaceuticals And Chemicals Limited has submitted to the Exchange the disclosure of shares pledged by promoter as required by regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 1997. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/Dishman_pledge_11022009.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that: 1) The Company has completed acquisition of land for its Pharmaceutical and Chemical SEZ, near Bavla. Total land acquired for its Pharmaceutical and Chemical SEZ is 390 Acres. Company further announces that land acquisition for its Engineering SEZ is on verge of completion and company will apply for notification of both the SEZ in next 15 to 30 days.Company has appointed a well-known firm,Ms.Multimedia Consultants as their consultant for both the SEZ for planning and engineering activities. Company expects to begin

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange regarding the outcome of Annual General Meeting held on July 31, 2008. A copy of the Outcome of AGM and notice of AGM shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DISHMAN_AGM_310072008.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that on and from August 05, 2008, the final dividend @50% as recommended by the Board and if declared by the members in the next Annual General Meeting as fixed on July 31, 2008, will be paid on 8,06,97,136 fully paid-up Equity Shares of Rs.2/- each. The dividend warrants will be paid at par at the centers and will be collected at par so as to reach all the holders of shares on time.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the Board meeting held on May 22, 2008, among others, the following decisions were taken by the Board of Directors of the Company : The Board has increased the Remuneration of Mrs. Deohooti. J. Vyas, whole-time Director of the Company from Rs. 3.00 lacs to Rs. 5.00 lacs per month w.e.f. 1st June, 2008 upon the recommendation of Remuneration Committee held today i.e. May 22, 2008. The Board has also decided for the payment of Remuneration by way of Commission in terms of the provisions of the Companies Act, 1956, to

Dishman Pharmaceuticals And Chemicals Limited has submitted to the Exchange the Audited Financial Results for the year ended March 31, 2008 as required under Clause 20 of the listing agreement i.e. Statement of Appropriations. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/dishman_UP_22052008.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the company has announced the Book Closure from July 19, 2008 to July 31, 2008 (both days inclusive) for determining the entitlement of final dividend, which was recommended by the Board @ 50% for the year 2007-08 and also for holding the Annual General Meeting on July 31, 2008.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Board of Directors at its meeting held on May 22, 2008 has recommended the final dividend @ 50% for the Financial Year 2007-08 on the paid-up equity share capital of the company.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that "Dishman Pharmaceuticals and Chemicals Ltd. ("the Company") announces that it has completed installation of three API (Active Pharmaceuticals Ingredient) Units at its Bavla facility at around cost of Rs.150 Crores, as "Project Taurus". The last (fourth) API facility will be dedicated for cytotoxic and cytotoxic compounds, such as Anti-Cancer Drugs, Hormones etc. This facility will be ready for commissioning before the end of the current calendar year".

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that: "Today, i.e. on 28th April, 2008, the Board of Directors of the Company has allotted 10,13,023 equity shares of Rs.2/- each of the Company at a premium of Rs.170/- per equity share upon exercise of option by a bondholder for conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US$ 4,000,000 into the equity shares of the Company. Consequently, the paid-up equity share capital of the Company has increased from 79684113 equity shares of Rs.2/- each to 80697136 equity shares of Rs.2/-

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that: "The Company has decided to publish audited financial results for the accounting year ended 31st March, 2008 within the stipulated period of 3 (three) months (i.e. on or before 30th June, 2008) from the end of the financial year 2007-2008 as stipulated in the listing agreement. Thus, the unaudited financial results for the last quarter of the accounting year ended 31st March, 2008 will not be published".

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that: "Today, i.e. on 17th March,2008, the Board of Directors of the Company has allotted 10,13,023 equity shares of Rs.2/- each of the Company at a premium of Rs.170/- per equity share upon exercise of option for conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US$ 4,000,000 into the equity shares of the Company, by a bondholder. Consequently, the paid-up equity share capital of the Company has increased from 78671090 equity shares of Rs.2/- each to 79684113 equity shares of Rs.2/-

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that: "Today, i.e. on 25th January, 2008, the Board of Directors of the Company has allotted 11,39,650 equity shares of Rs.2/- each of the Company at a premium of Rs.170/- per equity share upon exercise of option of conversion by the FCCB holders for conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US$ 4,500,000 into the equity shares of the Company. Consequently, the paid-up equity share capital of the Company, has increased from 77531440 equity shares of Rs.2/- each to 78671090 equ

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that: "Dishman Acquired Fine Chemicals and Vitamin D Business From Solvay. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)."<a href=/content/corporate/Dishman_acq_31102007.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that "Today i.e. on 29th September, 2007, the Board of Directors of the Company has allotted 10,13,023 equity shares of Rs.2/- each of the Company at a premium of Rs.170/- per equity share upon exercise of option of conversion by the FCCB holders for conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US$ 4,000,000, into the equity shares of the Company. Consequently, the paid-up equity share capital of the Company has increased from 76518417 equity shares of Rs.2/- each to 77531440 equ

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that: "Today i.e. on 10th September, 2007, the Board of Directors of the Company has allotted 2,53,255 equity shares of Rs.2/- each of the Company at a premium of Rs.170/- per equity share upon exercise of option of conversion by the FCCB holders for conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US$ 1,000,000, into the equity shares of the Company. Consequently, the paid-up equity share capital of the Company has increased from 76265162 equity shares of Rs.2/- each to 76518417 equ

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the Annual General Meeting of the Members / Shareholders of the Company held on August 07, 2007, members have approved and passed, among others, the following resolution: (1) in respect of the Financial Year 2006-2007, a dividend @ 50% (Rs.1.00 Per share) on the paid up equity shares of the Company has been declared by the members. All the resolutions proposed in the notice of the AGM have been passed by the members without any modification, in the AGM.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that on and from August 12, 2007, the final dividend @50% as recommended by the Board and if declared by the members in the next AGM as fixed on August 07, 2007 will be paid on 76265162 fully paid-up Equity Shares of rs.2/- each. The dividend warrants will be paid at par at the centers and will be collected at par so as to reach all the holders of shares on time.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that: "Today i.e. on 18th July, 2007, the Board of Directors of the Company has allotted 25,32,555 equity shares of Rs.2/- each of the Company at a premium of Rs.170/- per equity share upon exercise of option of conversion by the FCCB holders for conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US$ 10,000,000, into the equity shares of the Company. Consequently, the paid-up equity share capital of the Company has increased from 73732607 equity shares of Rs.2/- each to 76265162 equity

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange regarding an announcement, titled "Dishman signed MOU with Solvay". A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Dishman_PR_09072007.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that: "Today i.e. 18th June, 2007, the Board of Directors of the Company has allotted 6,33,137 equity shares of Rs.2/- each of the Company at a premium of Rs.170/- per equity share upon exercise of option of conversion by the FCCB holders for conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US$ 2,500,000, into equity shares of the Company. Consequently, the paid-up equity share capital of the Company has increased from 7,30,99,470 equity shares of Rs.2/- each to 7,37,32,607 equity sh

Dishman Pharmaceuticals And Chemicals Limited has submitted to the Exchange the Audited Financial Results for the year ended March 31, 2007 as required under Clause 20 of the listing agreement, i.e. Statement of Appropriations. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Dishman_20_29052007.zip target=NEW> For more details click here.</a>

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Board of the Directors of the Company held on May 28, 2007 inter alia considered the following : (1) The Board has recommended the final dividend @ 50% for the financial year 2006-07 on the paid-up equity share capital of the Company. (2) The Board has decided and resolved to convene and hold Annual General Meeting of the Members of the Company on August 07, 2007 and the Register of Members & Share Transfer Books of the Company will remain closed from July 28, 2007 to August 07, 2007 (both days inclusive) for det

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that: "Today i.e. 14th May, 2007, the Board of Directors of the Company has allotted 1,26,627 equity shares of Rs.2/- each of the Company at a premium of Rs.170/- per equity share upon exercise of option of conversion by the FCCB holders for conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US$ 500,000, into equity shares of the Company. Consequently, the paid-up equity share capital of the Company has increased from 7,29,72,843 equity shares of Rs.2/- each to 7,30,99,470 equity share